Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL-Reference-Cited by-同舟云学术

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

Published:2022-05-09 Issue:9 Volume:6 Page:2920-2926
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Northend Michael¹²,Wilson William²,Osborne Wendy³,Fox Christopher P.⁴^ORCID,Davies Andrew J.⁵^ORCID,El-Sharkawi Dima⁶^ORCID,Phillips Elizabeth H.⁷⁸,Sim Hau Wui⁹,Sadullah Shalal¹⁰,Shah Nimish¹¹,Peng Ying Ying¹²,Qureshi Iman¹³,Addada Juanah¹⁴,Mora Rocio Figueroa⁴,Phillips Neil¹⁵,Kuhnl Andrea¹⁶,Davies Elizabeth¹⁷^ORCID,Wrench David¹⁸,McKay Pamela¹⁹^ORCID,Karpha Indrani²⁰,Cowley Anna²¹,Karim Richard²²,Challenor Sarah²³^ORCID,Singh Vikram²⁴,Burton Cathy²⁵,Auer Rebecca²⁶,Williams Chris²⁷,Cunningham Joel¹⁰,Broom Angus²⁸,Arasaretnam Anita²⁹,Roddie Claire¹^ORCID,Menne Tobias³,Townsend William¹

Affiliation:

1. Department of Haematology, University College Hospital, London, United Kingdom;

2. Haematology Trials Team, Cancer Research United Kingdom & UCL Cancer Trials Centre, London, United Kingdom;

3. Department of Haematology, Freeman Hospital, The Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom;

4. Department of Haematology, Nottingham City Hospital, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom;

5. Southampton General Hospital, Southampton Cancer Research United Kingdom/National Institute for Health Research Experimental Cancer Medicines Centre, University of Southampton, Southampton, United Kingdom;

6. Department of Haematology, The Royal Marsden Hospital, Sutton, United Kingdom;

7. Department of Haematology, The Christie Hospital, Manchester, United Kingdom;

8. Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The Christie Hospital, Unit 26, University of Manchester, Manchester, United Kingdom;

9. Department of Haematology, Northwick Park Hospital, Middlesex, United Kingdom;

10. Department of Haematology, James Paget University Hospital, Great Yarmouth, United Kingdom;

11. Department of Haematology, Norfolk & Norwich University Hospital, Norwich, United Kingdom;

12. Department of Haematology, St George's Hospital, London, United Kingdom;

13. Department of Haematology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom;

14. Department of Haematology, Royal Derby Hospital, University Hospital of Derby & Burton NHS Foundation Trust, Derby, United Kingdom;

15. Department of Haematology, Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom;

16. Department of Haematology, King’s College Hospital, King’s College Hospital NHS Foundation Trust, London, United Kingdom;

17. Department of Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, United Kingdom;

18. Department of Haematology, Guy’s Hospital, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom;

19. Department of Haematology, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom;

20. Department of Haematology, The Clatterbridge Cancer Centre, Wirral, United Kingdom;

21. Department of Haematology, Eastbourne District Hospital, East Sussex Healthcare NHS Trust, Eastbourne, United Kingdom;

22. Department of Haematology, Dorset County Hospital, Dorchester, United Kingdom;

23. Department of Haematology, Royal Cornwall Hospital, Treliske, United Kingdom;

24. Department of Haematology, Aintree University Hospital, Liverpool, United Kingdom;

25. Department of Haematology, St James’ University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom;

26. Department of Haemato-Oncology, St Bartholomew’s Hospital, Bart’s Health NHS Trust, London, United Kingdom;

27. Department of Haematology, Hexham General Hospital, Northumbria Healthcare NHS Foundation Trust, Hexham, United Kingdom;

28. Department of Haematology, Western General Hospital, Edinburgh, United Kingdom; and

29. Department of Haematology, Royal Sussex County Hospital, Brighton & Sussex University Hospitals NHS Trust, Brighton, United Kingdom

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/6/9/2920/1895923/advancesadv2021005953.pdf

Reference18 articles.

1. Guidelines for the management of diffuse large B-cell lymphoma;Chaganti;Br J Haematol.,2016

2. Autologus bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma;Philip;N Engl J Med.,1995

3. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma;Schuster;N Engl J Med.,2019

4. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial;Locke;Lancet Oncol.,2019

5. Real-world data of high-grade lymphoma patients treated with CD19 CAR-T in England [abstract];Kuhnl;Blood.,2019

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of histologic, immunohistochemical and genomic features of large B cell lymphoma tumors may predict response to polatuzumab vedotin based therapy in patients with relapsed/refractory disease;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Antibody-drug conjugates: A review of cutaneous adverse effects;Journal of the American Academy of Dermatology;2024-07

3. Appropriate Treatment Intensity for Diffuse Large B-Cell Lymphoma in the Older Population: A Review of the Literature;Hematology Reports;2024-05-24

4. SOHO State of the Art Updates and Next Questions | Current Evidence and Future Directions for Bispecific Antibodies in Large B-Cell Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2024-05

5. Plasmablastic Lymphoma. A State-of-the-Art Review: Part 2-Focus on therapy;Mediterranean Journal of Hematology and Infectious Diseases;2024-02-29